Summit Therapeutics Inc. Board of Directors

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Prof. Dame Kay Davies DBE, FRS CBE

Prof. Dame Kay Davies DBE, FRS CBE

Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor

Dr. Mahkam Zanganeh D.D.S., M.B.A.

Dr. Mahkam Zanganeh D.D.S., M.B.A.

Co-CEO, President & Director

Dr. Fong Clow

Dr. Fong Clow

Chief Biometrics Officer

Mr. Robert W. Duggan

Mr. Robert W. Duggan

Co-CEO & Executive Chairman

Dr. Betty Y. Chang Ph.D.

Dr. Betty Y. Chang Ph.D.

Head of Research, Oncology & Inflammation

Ms. Shelley D. Spray

Ms. Shelley D. Spray

Chief Education & Brand Officer

Mr. Dave Gancarz

Mr. Dave Gancarz

Chief Business & Strategy Officer

Ms. Divya Chari

Ms. Divya Chari

Head of Global Clinical Operations

Mr. Bhaskar Anand

Mr. Bhaskar Anand

Chief Accounting Officer & Head of Finance

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.